Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy

A one-shot gene-editing cholesterol therapy could soon be a reality

GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health

Germany will be the first launch market

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Amneal and mAbxience score FDA green light for two Denosumab biosimilars

Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study

Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes

FDA expands Repatha indication to adults at risk of major cardiovascular events from uncontrolled LDL-C

The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia

Cardiological Society of India releases first Indian guidelines for dyslipidemia management

Dyslipidemia is a critical risk factor for cardiovascular diseases

Lupin receives approval from USFDA for Pitavastatin Tablets

Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol

Zydus receives final approval from the USFDA for Pitavastatin Tablets